Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQXP | ISIN: IL0011429839 | Ticker-Symbol: 5DT
Tradegate
08.08.25 | 09:53
1,490 Euro
-6,05 % -0,096
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENTERA BIO LTD Chart 1 Jahr
5-Tage-Chart
ENTERA BIO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,5741,63813:05
1,5261,64608.08.

Aktuelle News zur ENTERA BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrEntera Bio Ltd. - 10-Q, Quarterly Report1
FrEntera Bio Ltd.: Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates40FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignificant...
► Artikel lesen
28.07.Entera Bio stock surges after FDA agrees on BMD endpoint for EB6131
28.07.Entera Bio: Aktie legt nach positivem FDA-Bescheid für Osteoporose-Studie deutlich zu3
28.07.FDA agrees to BMD endpoint for Entera's oral osteoporosis drug1
ENTERA BIO Aktie jetzt für 0€ handeln
28.07.Entera Bio Ltd.: Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis214JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response...
► Artikel lesen
28.07.Entera Bio Ltd. - 8-K, Current Report1
23.07.OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)5
18.07.Entera Bio: Aktionäre genehmigen Vorstandswahl und Vergütungsvorschläge1
18.07.Entera Bio Ltd. - 8-K, Current Report1
25.06.OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting221MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo...
► Artikel lesen
30.05.Entera Bio files $100M mixed securities shelf2
30.05.Entera Bio Ltd. - S-8, Securities to be offered to employees in employee benefit plans1
09.05.Entera Bio GAAP EPS of -$0.06 beats by $0.011
09.05.Entera Bio Ltd.: Entera Bio Announces First Quarter 2025 Financial Results and Business Updates258JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key...
► Artikel lesen
09.05.Entera Bio Ltd. - 10-Q, Quarterly Report1
09.05.Entera Bio Ltd. - 8-K, Current Report-
09.05.Nagravision-Bango partnership brings over 100 subscription services to OpenTV ENTera8
07.05.Kudelski Group: NAGRAVISION Partners with Bango to Bring Over 100 Subscription Services to OpenTV ENTera, Driving Multi-Service Engagement for Telco Service Providers476Kudelski Group / Key word(s): Miscellaneous NAGRAVISION Partners with Bango to Bring Over 100 Subscription Services to OpenTV ENTera, Driving Multi-Service Engagement for Telco...
► Artikel lesen
15.04.Entera Bio reports positive phase 2 results for osteoporosis treatment14
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1